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Sensitivity to light was investigated 5 and 8 h after consumption of an amino
acid drink which contained L-tryptophan (balanced amino acid condition: 19
controls and 22 migraine sufferers) or which produced a short-term reduction in
brain serotonin synthesis by omitting L-tryptophan (tryptophan depletion con-
dition: 16 controls and 16 migraine sufferers). Migraine sufferers reported more
intense nausea, headache, glare- and light-induced pain than controls. In addi-
tion, glare- and light-induced pain were greater in the tryptophan depletion
condition than in the balanced amino acid condition, in both migraine sufferers
and controls. Eight hours after the amino acid drink, after participants had
completed tests of pain sensitivity and motion sickness provocation, tryptophan
depletion augmented headache in migraine sufferers and aggravated nausea in
migraine sufferers and controls. These ﬁndings suggest that a reduction in brain
synthesis of serotonin intensiﬁes photophobia and other migrainous symptoms
and thus might contribute to the pathogenesis of migraine. Headache, migraine
pathogenesis, nausea, photophobia, serotonin, visual stimulation
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Introduction
Serotonin (5-HT) has long been implicated in the
pathogenesis of migraine (1). Susceptibility to
migraine is associated with chronically low concen-
trations of plasma serotonin (2) and heightened
sensitivity to serotonin agonists (3), possibly due to
a disturbance in the metabolism of serotonin (2). In
addition, alterations in the sensitivity of serotoner-
gic receptors or turnover of serotonin in the central
nervous system (1, 4) could contribute to interictal
abnormalities in sensory processing such as attenu-
ated habituation of cortical evoked responses in
migraineurs (5). During attacks of migraine, sero-
tonin is released from platelets into blood plasma,
possibly mirroring a disturbance in serotonin turn-
over in the central nervous system (6).
The 5-HT1A,2B/C agonist m-chlorophenylpiperazine
provokes migrainous symptoms (7) and headache
in migraine sufferers (8). The headache builds up
several hours after plasma concentrations and car-
diovascular effects peak, apparently during a
period of relative reduction in serotonin activity
following stimulation of serotonin receptors (8).
Drugs such as fenﬂuramine and reserpine, that
release and then deplete endogenous stores of sero-
tonin, also induce headache within a few hours in
susceptible people (3, 9, 10). Headache sometimes
develops before blood serotonin concentrations
decline (9, 10), suggesting that the headache is
triggered by neural rather than systemic depletion
of serotonin.
Rapid tryptophan depletion produces a short-
term reduction in brain serotonin synthesis and has
been employed in human studies to investigate the
adverse effect of this reduction on mood disorders
such as depression (11, 12). In rats, a low-
tryptophan diet or tryptophan-free amino acid
mixture decreases spontaneous and d-fenﬂuramine-
induced release of serotonin and its metabolite
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cellular ﬂuid of the hippocampus (13, 14). In
humans, tryptophan depletion markedly dimin-
ishes serotonin synthesis, measured by positron
emission tomographic scanning using a-
11C-methyl-
L-tryptophan as a tracer, both in cortical and sub-
cortical regions of the brain (15). In addition,
concentrations of 5-HIAA in the cerebrospinal ﬂuid
fall around 30% several hours after tryptophan
depletion, indicating that central serotonin turnover
declines substantially (16, 17).
Tryptophan depletion does not trigger full-blown
attacks of migraine (11, 18), but may heighten sus-
ceptibility to migrainous symptoms (18). The effect
of tryptophan depletion on susceptibility to motion
sickness provoked by optokinetic stimulation was
investigated recently in our laboratory (18). In
general, vestibular symptoms such as nausea and
dizziness were greater in migraine sufferers than in
controls during optokinetic stimulation. In addition,
tryptophan depletion increased susceptibility to
these symptoms in controls, thus raising the possi-
bility that a chronically low concentration of brain
serotonin increases susceptibility to vestibular dis-
turbances in migraine sufferers.
The aim of the present study was to determine
whether tryptophan depletion would augment pho-
tophobia, one of the hallmarks of migraine. During
the headache-free interval, bright light and high-
contrast striped patterns induce greater discomfort
in migraine sufferers than in controls (19–25). Pho-
tophobia increases in migraine sufferers during
painful stimulation of the face (20, 26) and during
migrainous attacks (19, 24, 25). The mechanism of
photophobia is unclear, but could involve conver-
gence of visual and trigeminal nociceptive activity
in the thalamus or superior colliculus. In patients
with ocular disease, irritation or inﬂammation of
structures supplied by trigeminal nociceptive affer-
ents (e.g. the iris, cornea or conjunctiva) contributes
to photophobia (27). Photophobia also develops in
patients with trigeminal neuralgia and after infec-
tion or lesions that involve pain-sensitive structures
at the base of the brain (e.g. meningitis, subarach-
noid haemorrhage or tumours around the optic
chiasm) (28–30). Spatial summation of visual input
in the central nervous system contributes to
photophobia—the brightness (radiance) of a visual
stimulus required to elicit visual discomfort is less
for large than for small areas of retinal stimulation
(31) and is lower for binocular than monocular
stimulation (24, 32). Serotonergic neurons in the
dorsal raphe nucleus send axon collaterals to mul-
tiple cortical and subcortical trigeminal somatosen-
sory targets (33). A large serotonergic projection
from the dorsal raphe nucleus also terminates in the
superior colliculus (34), a potential site of visual and
trigeminal nociceptive convergence (35, 36). As sero-
tonin generally exerts an inhibitory inﬂuence on
discharge of visual and nociceptive neurons (34, 37),
depletion of serotonin might enhance photophobia.
In a previous study in our laboratory (38), pho-
tophobia persisted during a 30-min recovery period
after optokinetic stimulation in migraine sufferers
but decreased in controls. Hence, photophobia was
investigated before and after optokinetic stimula-
tion in the present study, to determine the com-
bined effect of tryptophan depletion, residual
nausea and headache on photophobia. Lebensohn
and Bellows (27) distinguished between painless
glare or dazzle—possibly due to thalamic dysfunc-
tion (39)—and pain induced by bright light in
patients with painful ocular or intracranial disease.
Thus, both glare and light-induced pain were exam-
ined in the present study. It was hypothesized that
photophobia would be greater in the tryptophan
depletion condition than in a balanced amino acid
condition and that this would be most evident in
the presence of residual symptoms provoked by
optokinetic stimulation.
Methods
Subjects
The migraine sample consisted of 32 women and
six men aged between 18 and 57 years (mean  SD
35.1  13.8 years) who met diagnostic criteria (40)
for migraine with aura (n = 8) or migraine without
aura (n = 30) and who suffered from one or more
headache episodes each month. The controls con-
sisted of 26 healthy women and nine men aged
between 19 and 59 years (mean age 36.7 
14.1 years) without a history of migraine who expe-
rienced six or fewer mild headaches per year. The
facilitatory effects of tryptophan depletion in these
participants on symptoms provoked by optokinetic
stimulation have been reported previously (18).
Migraine sufferers were tested when they had been
free from headache for 9.3  7.5 days and women
were tested between menstrual periods. Apart from
the oral contraceptive, none of the participants took
preventative medicine for migraine or for any other
condition.
Each participant provided informed consent
for the procedures, which were approved by the
Murdoch University Human Research Ethics
Committee.
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The procedures were carried out in a temperature-
controlled room, maintained at 23  1°C. Partici-
pants had a light protein-free breakfast without
caffeine and reported to the laboratory around
08.00 h. The synthesis of serotonin depends on
dietary intake of tryptophan, the amino acid precur-
sor of serotonin. Ingestion of a tryptophan-free
mixture of amino acids provokes a large and rapid
fall in plasma tryptophan by stimulating protein
synthesis in the liver. In addition, competition
between tryptophan and other large amino acids for
transport across the blood–brain barrier restricts the
entry of tryptophan into the brain, thereby decreas-
ing the synthesis of serotonin in brainstem projection
neurons (the main source of serotonin in the central
nervous system) (12). Thus, to accomplish rapid
tryptophan depletion, participants consumed cap-
sules and a drink containing 5.5 g L-alanine, 4.9 g
L-arginine, 2.7 g L-cysteine, 3.2 g glycine, 3.2 g
L-histidine, 8.0 g L-isoleucine, 13.5 g L-leucine, 8.9 g
L-lysine, 3.0 g L-methionine, 5.7 g L-phenylalanine,
12.2 g L-proline, 6.9 g L-serine, 6.5 g L-threonine,
6.9 g L-tyrosine and 8.9 g L-valine (12, 18). Amino
acids with an unpalatable texture or taste were
encapsulated and ﬂavouring was added to the drink
to disguise further the unpleasant taste. In the
balanced amino acid condition, 2.3 g L-tryptophan
was added to the drink. Participants were allocated
randomly to the tryptophan depletion condition (16
controls and 16 migraine sufferers) or the balanced
amino acid condition (19 controls and 22 migraine
sufferers). Neither the participant nor the research
assistant who administered the procedures was
aware of the tryptophan content of the drink. Blood
samples were taken before the amino acids were
ingested and approximately 4.5 h and 7.5 h later.
Concentrations of unbound tryptophan in blood
plasma were analysed using high-pressure liquid
chromatography and were found to be diminished
by 88  9% at 4.5 h and 78  25% at 7.5 h in the
tryptophan deletion condition. In contrast, plasma
tryptophan concentrations were 206  172% above
baseline at 4.5 h and 33  69% above baseline at 7.5 h
in the balanced amino acid condition. As reported
elsewhere (18), platelet serotonin concentrations did
not differ between migraine sufferers and controls or
between the tryptophan depletion and balanced
amino acid conditions at any stage of the experi-
ment, presumably because of low turnover of sero-
tonin in the systemic circulation.
Sensitivity to light was investigated approxi-
mately 5 h and 8 h after the amino acids were
ingested. During the 3-h interval between the two
tests of light sensitivity, participants completed a
range of neurophysiological and sensory tests that
aimed to investigate the effect of tryptophan deple-
tion on symptoms and signs of migraine. In par-
ticular, blink reﬂexes to electrical stimulation of the
supraorbital nerve were recorded before and during
limb and cranial pain induced by ice (unpublished
observations), followed by optokinetic stimulation
that involved a visual illusion of movement created
by watching black and white stripes move past for
15 min or until vomiting was imminent (18). The
second test of light sensitivity began approximately
20 min after termination of optokinetic stimulation,
when some participants were still experiencing
residual symptoms of motion sickness. The inten-
sity of nausea and headache was rated before and
after each test of light sensitivity on scales where 0
corresponded to ’no sensation at all’ and 10 to
’extreme’.
During each test of light sensitivity, the partici-
pant sat approximately 80 cm in front of a 50-W
halogen globe located behind a translucent plastic
screen. Electrical power to the halogen globe was
controlled by a computer to produce three levels
of screen luminance (90 cd/m
2, 4100 cd/m
2 and
19 800 cd/m
2 measured with a Photo Research
Spectra spotmeter, Model PR1500; Chatsworth, CA,
USA). Twenty seconds after light onset, the partici-
pant rated glare- and light-induced pain between 0
and 10, where 0 corresponded to ’not at all’ and 10
to ’extreme’. The participant then waited for 30 s in
darkness before the next trial began. Each level of
light intensity was presented three times in random
order.
Data reduction and statistical approach
Mean glare and pain ratings for each level of
light intensity were investigated separately in
2 ¥ 2 ¥ 2 ¥ 3 [Group (migraine, control) ¥ Condition
(tryptophan depletion, balanced amino acids) ¥ Test
(ﬁrst, second) ¥ Light Intensity (dim, moderately
bright, bright)] analyses of variance. Similarly,
nausea and headache ratings were investigated
separately in Group ¥ Condition ¥ Test ¥ Pre-Post
(before vs. after each test) analyses of variance. The
multivariate solution was used for factors with
more than two levels because the multivariate
approach does not require assumptions of spheric-
ity of the variance–covariance matrix to be met (41).
The criterion of statistical signiﬁcance was P  0.05
and only signiﬁcant main effects and interactions
are reported.
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Ratings of glare and light-induced pain
As shown in Fig. 1, glare ratings were greatest for
bright light [main effect for Light Intensity:
F(2,68) = 365.9, P  0.001] and increased from
before to after optokinetic stimulation [main effect
for Test: F(1,69) = 17.4, P  0.001]. Glare was greater
in migraine sufferers than in controls both before
and after optokinetic stimulation [main effect for
Group: F(1,69) = 4.03, P  0.05] and was greater
throughout the experiment for participants in the
tryptophan depletion condition than in the bal-
anced amino acid condition [main effect for Condi-
tion: F(1,69) = 6.76, P  0.05].
Ratings of light-induced pain also were greatest
for bright light [main effect for Light Intensity:
F(2,68) = 27.3, P  0.001] (Fig. 1). Light-induced
pain was greater in migraine sufferers than in con-
trols both before and after optokinetic stimulation
[main effect for Group: F(1,69) = 7.48, P  0.01], par-
ticularly at the brighter intensities of light [Group–
Light Intensity interaction: F(2,68) = 3.69, P  0.05]
(Fig. 1). Light-induced pain increased after optoki-
netic stimulation in migraine sufferers but not in
controls [Group–Test interaction, F(1,69) = 6.89,
P  0.05] and was greater throughout the experi-
ment for participants in the tryptophan depletion
condition than in the balanced amino acid
condition [main effect for Condition: F(1,69) = 4.19,
P  0.05].
Nausea and headache before and after each test of
light sensitivity
Nausea was greater in migraine sufferers than in
controls throughout the experiment [main effect for
Group, F(1,69) = 11.9, P  0.001] (Fig. 2). Nausea
remained relatively stable in migraine sufferers and
controls in the balanced amino acid condition, but
increased after optokinetic stimulation for partici-
pants in the tryptophan depletion condition [main
effect for Test, F(1,69) = 11.6, P  0.001; Condition–
Test interaction, F(1,69) = 5.01, P  0.05]. Nausea
did not increase during the tests of light sensitivity
(neither the Pre–Post main effect nor interactions
that included this factor achieved statistical
signiﬁcance).
In general, headache ratings were low through-
out the experiment and the headaches did not meet
diagnostic criteria for migraine. Nevertheless,
headache was greater in migraine sufferers than in
controls [main effect for Group, F(1,69) = 25.9,
P  0.001] and increased during the tests of light
sensitivity in migraine sufferers but not in controls
[Group ¥ Pre–Post interaction, F(1,69) = 10.5,
P  0.01] (Fig. 3). In addition, headache increased
after optokinetic stimulation [main effect for Test,
F(1,69) = 4.62, P  0.05], notably in migraine
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Figure 1 Ratings of glare and light-induced pain (SEM) in migraine sufferers and controls in the tryptophan depletion
and balanced amino acid conditions, during exposure to dim light, moderately bright light, and bright light before (test 1)
and after optokinetic stimulation (test 2).
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[Group ¥ Condition–Test interaction, F(1,69) = 5.29,
P  0.05] (Fig. 3).
Discussion
Ratings of glare- and light-induced pain were
greater in the tryptophan depletion condition than
in the balanced amino acid condition, in both
migraine sufferers and headache-free controls. In
addition, tryptophan depletion augmented head-
ache in migraine sufferers and enhanced nausea in
migraine sufferers and controls after they had com-
pleted tests of pain sensitivity and motion sickness
provocation. As tryptophan depletion lowers levels
of serotonin in the brain (13–17) but not in the
systemic circulation (18), these ﬁndings suggest that
a reduction in brain synthesis of serotonin aggra-
vates symptoms of migraine.
Irrespective of tryptophan depletion, migraine
sufferers reported more intense nausea, headache,
glare and light-induced pain than participants who
rarely or never suffered from headache. These ﬁnd-
ings concur with many previous reports (18–25)
and indicate that symptoms of migraine develop
readily in migraine sufferers during the headache-
free interval. Whether this is a cause or effect of the
migraine predisposition is uncertain. However, it
seems reasonable to speculate that interictal hyper-
excitability of the trigeminal system in migraine
sufferers (42–44) increases vulnerability to headache
and possibly also to photophobia (20, 26).
Sensitivity to light during attacks of migraine
forms part of a global sensitivity to noise, odours,
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Figure 2 Nausea ratings (SEM) in migraine sufferers and controls in the tryptophan depletion and balanced amino acid
conditions, before () and after each test of light sensitivity (). Nausea increased during the interval between the ﬁrst
and second test of light sensitivity for migraine sufferers and controls in the tryptophan depletion condition (*P  0.05).
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cause of sensory hypersensitivity (e.g. disruption to
inhibitory serotonergic modulation of sensory
input) (45). In the present study, ratings of glare and
light-induced pain were greater in the tryptophan
depletion condition than in the balanced amino
acid condition. One potential explanation for this
ﬁnding is that serotonergic neurons with multiple
projections (e.g. from the dorsal raphe nucleus
to the thalamus and superior colliculus) (33, 34)
inhibit both the painless and painful components of
photophobia.
In another part of this study, tryptophan deple-
tion enhanced symptoms of motion sickness
(nausea, dizziness and a sense of spinning) in
control participants to levels approaching those of
migraine sufferers (18). To determine whether
residual symptoms of motion sickness would
augment effects of tryptophan depletion on photo-
phobia in the present study, the second test of light
sensitivity began approximately 20 min after termi-
nation of the optokinetic stimulus that induced
motion sickness. Nausea and headache were greater
after than before optokinetic stimulation for
migraine sufferers in the tryptophan depletion con-
dition, but remained unchanged in the balanced
amino acid condition. Similarly, nausea was greater
after than before optokinetic stimulation for con-
trols in the tryptophan depletion condition. As
nausea was minimal in controls before optokinetic
stimulation (mean rating 0.2  0.1 on a 0–10 scale)
(18), tryptophan depletion apparently inhibited
the resolution of motion sickness. Photophobia
increased after optokinetic stimulation—glare
increased in migraine sufferers and controls and
light-induced pain increased in migraine sufferers.
In addition, both in migraine sufferers and controls,
glare- and light-induced pain were greater during
Controls:
balanced amino acids
Test 1 Test 2
0
1
2
3
H
e
a
d
a
c
h
e
 
r
a
t
i
n
g
H
e
a
d
a
c
h
e
 
r
a
t
i
n
g
H
e
a
d
a
c
h
e
 
r
a
t
i
n
g
H
e
a
d
a
c
h
e
 
r
a
t
i
n
g
Controls:
 tryptophan depletion
Migraine:
balanced amino acids
Migraine:
 tryptophan depletion
Test 1 Test 2
0
1
2
3
Test 1 Test 2
0
1
2
3
Test 1 Test 2
0
1
2
3
*
Figure 3 Headache ratings (SEM) in migraine sufferers and controls in the tryptophan depletion and balanced amino
acid conditions, before () and after each test of light sensitivity (). Headache increased during the interval between the
ﬁrst and second test of light sensitivity for migraine sufferers in the tryptophan depletion condition (*P  0.05).
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tion condition than in the balanced amino acid
condition. Taken together, the ﬁndings suggest that
the migraine predisposition, tryptophan depletion
and residual symptoms of motion sickness augment
photophobia. Clearly, these effects are not entirely
independent of each other, because both the
migraine predisposition and tryptophan depletion
augmented residual motion sickness.
In previous studies in our laboratory, head pain
was found to aggravate nausea and photophobia in
migraine sufferers (20, 26, 46); conversely, nausea
aggravated headache and scalp tenderness (38, 47).
In addition, visual stimulation that provoked pho-
tophobia in migraine sufferers also heightened
scalp tenderness (20, 48). Thus, symptoms of
migraine appear to build upon each other during
the headache-free interval, perhaps in a vicious
circle. Although a reduction in brain serotonin syn-
thesis might contribute to this synergistic process,
some other factor must also be involved because
tryptophan-depleted controls remained headache
free and photophobia did not increase over the
course of the present study, despite an increase in
nausea. In contrast, headache increased during
visual stimulation in migraine sufferers and photo-
phobia increased in line with increases in headache
as the experiment progressed. The link between
headache and photophobia in migraine sufferers is
consistent with many other observations that im-
plicate trigeminal nociceptive involvement in
photophobia (27, 30).
One limitation of the present study is that the
sample size was too small to compare effects of
tryptophan depletion in migraine sufferers with and
without aura. The effect of serotonin depletion with
para-chlorophenylalanine, a tryptophan hydroxy-
lase inhibitor, on spreading depression of neural
activity in the cerebral cortex (a model of the
migraine aura) was investigated recently in rats (49).
Serotonin depletion increased the number of waves
of spreading depression induced by topical applica-
tion of potassium chloride on the parietal cortex.
Moreover, expression of c-fos-immunoreactivity in
neurons in the trigeminal nucleus caudalis was
greater ipsilateral than contralateral to the cortical
spreading depression, and was greater bilaterally in
serotonin-depleted rats than in controls. These ﬁnd-
ings suggest that cortical application of potassium
chloride evokes activity in trigeminal nociceptive
neurons and that serotonin depletion facilitates this
activity. Thus, it would be interesting to determine
whether tryptophan depletion alters cortical activity
(indexed, for example, by cortical evoked responses)
and whether this response differs between migraine
sufferers with and without aura.
In conclusion, the present ﬁndings suggest that a
reduction in brain synthesis of serotonin intensiﬁes
nausea, headache and photophobia. Hence, correct-
ing this deﬁciency could prevent these symptoms
from escalating before and during migrainous
attacks and, in the longer term, reduce vulnerability
to migraine. Tryptophan depletion could be a useful
tool for investigating the effect of new treatments
that target central serotonin turnover or that aim to
block symptoms of migraine.
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